Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Cyclically Adjusted Revenue per Share: €1.07 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:08HH Shanghai Fosun Pharmaceutical (Group) Co Ltd STU:08HH
71 GF Score
Price €1.79
GF Value €2.24
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share?

Shanghai Fosun Pharmaceutical (Group) Co STU:08HH -1.40% 71 Cyclically Adjusted Revenue per Share is €1.07 as of Mar. 2026. GuruFocus rates STU:08HH with a GF Score™ of 71/100 and a GF Value™ of €2.24 (Modestly Undervalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Shanghai Fosun Pharmaceutical (Group) Co's adjusted revenue per share for the three months ended in Mar. 2026 was €0.479. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.07 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Shanghai Fosun Pharmaceutical (Group) Co's average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Shanghai Fosun Pharmaceutical (Group) Co was 17.20% per year. The lowest was 9.00% per year. And the median was 12.55% per year.

As of today (2026-08-03), Shanghai Fosun Pharmaceutical (Group) Co's current stock price is €1.7905. Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €1.07. Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio of today is 1.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shanghai Fosun Pharmaceutical (Group) Co was 10.49. The lowest was 1.60. And the median was 4.64.


Shanghai Fosun Pharmaceutical (Group) Co  (STU:08HH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.7905/1.07
=1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shanghai Fosun Pharmaceutical (Group) Co was 10.49. The lowest was 1.60. And the median was 4.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share Related Terms


Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.85 0.84 0.82 1.02

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.88 1.15 1.02 1.07

STU:08HH vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio falls into.


STU:08HH
71GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd STU:08HH
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shanghai Fosun Pharmaceutical (Group) Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.479/116.3033*116.3033
=0.479

Current CPI (Mar. 2026) = 116.3033.

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.221 101.400 0.253
201609 0.212 102.400 0.241
201612 0.227 102.600 0.257
201703 0.221 103.200 0.249
201706 0.232 103.100 0.262
201709 0.234 104.100 0.261
201712 0.285 104.500 0.317
201803 0.291 105.300 0.321
201806 0.334 104.900 0.370
201809 0.294 106.600 0.321
201812 0.339 106.500 0.370
201903 0.349 107.700 0.377
201906 0.368 107.700 0.397
201909 0.362 109.800 0.383
201912 0.366 111.200 0.383
202003 0.302 112.300 0.313
202006 0.392 110.400 0.413
202009 0.395 111.700 0.411
202012 0.400 111.500 0.417
202103 0.405 112.662 0.418
202106 0.450 111.769 0.468
202109 0.516 112.215 0.535
202112 0.657 113.108 0.676
202203 0.586 114.335 0.596
202206 0.600 114.558 0.609
202209 0.557 115.339 0.562
202212 0.627 115.116 0.633
202303 0.552 115.116 0.558
202306 0.514 114.558 0.522
202309 0.434 115.339 0.438
202312 0.498 114.781 0.505
202403 0.489 115.227 0.494
202406 0.493 114.781 0.500
202409 0.490 115.785 0.492
202412 0.510 114.893 0.516
202503 0.456 115.116 0.461
202506 0.455 114.907 0.461
202509 0.446 115.471 0.449
202512 0.562 115.832 0.564
202603 0.479 116.303 0.479

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.07 mean?
Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) has a Cyclically Adjusted Revenue per Share of €1.07 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Cyclically Adjusted Revenue per Share is €1.07. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share of €1.07 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Cyclically Adjusted Revenue per Share is €1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.24, compared to a current price of €1.79 — trading 20.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.07. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH), the current Cyclically Adjusted Revenue per Share is €1.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of €1.79 is trading 20.1% below its estimated GF Value™ of €2.24. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for STU:08HH:

  • Cyclically Adjusted Revenue per Share: €1.07
  • GF Value™: €2.24 vs. price of €1.79 (20.1% below fair value)
  • GF Score™: 71/100 with 10 warning signs

No single metric tells the full story. See the STU:08HH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
71GF Score

Get the complete analysis for STU:08HH

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.79
Price
€2.24
GF Value